Table 2.
Baseline and follow-up clinical data, descriptive analysis and their associations with Functional outcome
| Dichotomized and ordinal variables | ||||||
|---|---|---|---|---|---|---|
| All patients n (%) | Functional outcome | Association with favorable outcome | ||||
| Favorable n (%) | Unfavorable n (%) | OR (95%CI) | p | |||
| All patients | 221(100%) | 131(59.3%) | 90(40.7%) | |||
| Sex | Female | 111(50.2%) | 64(48.9%) | 47(52.2%) | 0.6(0.3–1.3) | 0.20 |
| Male | 110(49.8%) | 67(51.1%) | 43(47.8%) | |||
| Occlusion location | ICA | 14(6.3%) | 8(6.1%) | 6(6.7%) | 4.6(0.4–51.0) | 0.21 |
| M1 | 94(42.5%) | 45(34.4%) | 49(54.4%) | 4.1(0.5–31.9) | 0.18 | |
| M2 | 67(30.3%) | 45(34.4%) | 22(24.4%) | 3.3(0.4–25.0) | 0.25 | |
| M3 and M4 | 18(8.1%) | 16(12.2%) | 2(2.2%) | 7.0(0.6–87.3) | 0.13 | |
| Basilar | 6(2.7%) | 4(3.1%) | 2(2.2%) | 2.7(0.1–51.3) | 0.51 | |
| PCA | 17(7.7%) | 11(8.4%) | 6(6.7%) | 2.7(0.3–26.6) | 0.39 | |
| ACA | 5(2.3%) | 2(1.5%) | 3(3.3%) | |||
| Treated with antithrombolitics | no | 159(73.3%) | 92(71.3%) | 67(76.1%) | 0.4(0.1–2.0) | 0.29 |
| yes | 58(26.7%) | 37(28.7%) | 21(23.9%) | |||
| Treatment | None | 49(22.3%) | 30(22.9%) | 19(21.3%) | 0.3(0.0–5.6) | 0.44 |
| IV-TPA | 82(37.3%) | 47(35.9%) | 35(39.3%) | 1.4(0.1–15.6) | 0.78 | |
| IA-TPA | 25(11.4%) | 13(9.9%) | 12(13.5%) | 1.7(0.1–22.2) | 0.69 | |
| IV+IA-TPA | 58(26.4%) | 36(27.5%) | 22(24.7%) | 4.6(0.4–59.2) | 0.24 | |
| Tenecteplase | 6(2.7%) | 5(3.8%) | 1(1.1%) | |||
| Continuous variables | ||||||
| Unit | Median(IQR) | Functional outcome | Association with favorable outcome | |||
| Favorable | Unfavorable | OR (95%CI) | p | |||
| Age | Year | 73 (62–80) | 71(58–77) | 77(69–84) | 0.96(0.93–0.98) | 0.002 |
| Hematocrit | % | 0.42 (0.38–0.45) | 0.42(0.40–0.45) | 0.41(0.36–0.45) | 11.2(0.0–6405.7) | 0.46 |
| NIHSS | score | 12 (6–19) | 9(5–15) | 18(12–23) | 0.82(0.77–0.88) | <0.001 |
TAI thrombus attenuation increase, HU Hounsfield unit, OR odds ratio, CI confidence interval, p significance value, IQR interquartile range, TiCTA time invariant computed tomography angiography, IV-rtPA intravenous recombinant tissue-type plasminogen activator treatment, IA-TPA intra-arterial recombinant tissue-type plasminogen activator treatment; mRS modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale, ACA anterior cerebral artery, ICA intracranial cerebral artery, M1 sphenoidal segment of the middle cerebral artery, M2 insular segment of the middle cerebral artery, M3 opercular segment of the middle cerebral artery, M4 cortical segment of the middle cerebral artery, PCA posterior cerebral artery mRS score: 0, no symptoms at all; 1, no significant disability despite symptoms; 2, slight disability; 3, moderate disability; 4, moderately severe disability; 5, severe disability; 6, dead; and for italic values, p is significant at the 0.05 level